VIDEO: Amivantamab plus chemo effective post-osimertinib in EGFR-mutated NSCLC
Click Here to Manage Email Alerts
MADRID — Healio spoke with Hossein Borghaei, DO, MS, about the results of the MARIPOSA-2 trial, which were presented at ESMO Congress.
In the phase 3 randomized trial, patients with EGFR-mutated advanced non-small cell lung cancer who had progressed on osimertinib (Tagrisso, AstraZeneca) received amivantamab (Rybrevant, Janssen) plus chemotherapy, amivantamab plus chemotherapy with lazertinib (Leclaza; Yuhan, Janssen), or chemotherapy alone.
Compared with chemotherapy alone, amivantamab plus chemo— both with or without the addition of lazertinib — improved PFS in these patients.
“What I take away from this study is that the combination of amivantamab plus chemo can be very effective post-osimertinib, but I’m not sure that the addition of lazertinib is necessarily adding a whole lot,” said Borghaei, chief of the division of thoracic medical oncology at Fox Chase Cancer Center.
Noting the additional toxicities, Borghaei questioned whether it’s “appropriate to offer the triple combination.”
He added, “this always becomes a balance of efficacy vs. toxicity.”
“Nonetheless, I think this offers a potentially different treatment option for at least some of our patients,” he said.
Reference:
- Passaro A, et al. Abstract LBA15. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts